Similar articles

• [Lower, lower, lower. The LDL goal value of 200 mg/dl is still much too high].

  Einecke D. Einecke D. MMW Fortschr Med. 2004 Mar 25;146(13):4-5. MMW Fortschr Med. 2004. PMID: 15219114 German. No abstract available.
• Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.

  Colquhoun D, Keech A, Hunt D, Marschner I, Simes J, Glasziou P, White H, Barter P, Tonkin A; LIPID Study Investigators. Colquhoun D, et al. Eur Heart J. 2004 May;25(9):771-7. doi: 10.1016/j.ehj.2004.03.013. Eur Heart J. 2004. PMID: 15120888 Clinical Trial.
• Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.

  Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, Shepherd J. Simes J, et al. Eur Heart J. 2002 Feb;23(3):207-15. doi: 10.1053/euhj.2001.2775. Eur Heart J. 2002. PMID: 11792135 Clinical Trial.
• Intensive statin therapy in coronary artery disease: is lower cholesterol better and safe?

  Seshasai SR, Ray KK. Seshasai SR, et al. Future Cardiol. 2009 Mar;5(2):129-39. doi: 10.2217/14796678.5.2.129. Future Cardiol. 2009. PMID: 19371188 Review.
• Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.

  Nissen SE. Nissen SE. Am J Cardiol. 2005 Sep 5;96(5A):61F-68F. doi: 10.1016/j.amjcard.2005.07.013. Am J Cardiol. 2005. PMID: 16126025 Review.